Suchergebnisse
Suchergebnisse:
16. Nov. 2018 · Adrenomed AG. @adrenomed. An innovative biomarker-guided #precisionmedicine solution for patients in acute care with #sepsis and #septicshock. #enibarcimab. Hennigsdorf, Deutschland adrenomed.com Joined November 2018. 218 Following.
AdrenoMed is dedicated to saving the lives of critically ill patients by translating the concept of personalized medicine to acute care. We are targeting Adrenomedullin, a peptide hormone with protective effects on endothelial barrier integrity.
13. Okt. 2022 · In #November, meet our CEO and CFO at: @LSXLeaders’ Inv€$tival #Showcase November 14, 2022, in-person in #London, UK. 13 Oct 2022 07:41:09
10. Apr. 2024 · AdrenoMed is now preparing a confirmatory Phase IIb/III clinical trial to confirm the reduced septic shock mortality under enibarcimab treatment employing a precision medicine approach.
Adrenomed AG is a German privately financed, clinical-stage biopharmaceutical company. Adrenomed’s mission is to rescue vascular integrity in order to save the lives of critically ill...
19. Okt. 2021 · Der Biochemiker Andreas Bergmann will den ersten Wirkstoff gegen Sepsis zur Marktreife bringen. Investoren halten das Projekt Adrenomed für vielversprechend.
13. Okt. 2022 · Hennigsdorf/Berlin (Germany), September 8, 2023 – Adrenomed AG, the vascular integrity company, today announced new findings on the biomarker-guided treatment of septic shock with enibarcimab. New data analyses of the phase II clinical trial AdrenOSS-2 validate.
